IGHE and Alzheimer disease: For the low-baseline-IgE group of patients with AD, to neutralize 90% of IgE (EC90) (Figure 7B) may require 1.0 μg/mL UB-221 or ligelizumab, while a more than 4-fold greater concentration, 4.3 μg/mL, would be needed for omalizumab (Figure 7C).